TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02140099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationships Plus Program (HRPP)
Description: The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Condition (Classroom Activities)
Study: NCT02293655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OROS-Methylphenidate (MPH)
Description: OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS-Methylphenidate (MPH)
Description: OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
Study: NCT03566368

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiogram
Description: a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic Echocardiogram
Description: Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac enzyme - Troponin I Levels
Description: Blood sample - venous collected to measure blood troponin - I levels.
Study: NCT02558257

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
Study: NCT03679910

Intervention type: DIAGNOSTIC_TEST
Intervention: CEMIP , CA19-9 ,CEA
Description: CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen

Intervention type: DIAGNOSTIC_TEST
Intervention: CEMIP , CA19-9 ,CEA
Description: CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen

Intervention type: DIAGNOSTIC_TEST
Intervention: A) CBC . B) RBG. C)KFT. D) LFT.
Description: A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: A) CBC . B) RBG. C)KFT. D) LFT.
Description: A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
Study: NCT00413192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389
Description: 1.4 mg/m\^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
Study: NCT01769833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-interferon-Alfa-2A
Description: Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nucleosides
Study: NCT03696810

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Laboratory tests
Description: • Laboratory tests (HbA1C levels and lipids)
Study: NCT03318315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza H7N9 vaccine
Description: Monovalent 2017 H7N9 inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
Study: NCT02475577

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherals with HealthInterlink technology
Description: home remote monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherals with HealthInterlink technology
Description: home remote monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripherals with HealthInterlink technology
Description: home remote monitoring
Study: NCT01985360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Graft Surgery
Description: Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: Diet, physical activity, smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: Diet, physical activity, smoking cessation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
Study: NCT01300455

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suvorexant
Description: 40 mg tablets, orally once daily for 4 consecutive days in the evening
Study: NCT00774592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caribbean Informed Parents and Children Together (CImPACT)
Description: CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bahamian Focus on Older Youth (BFOOY)
Description: 10 session HIV prevention program
Study: NCT01300455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 40 mg tablets, orally once daily for 4 consecutive days in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo tablets, orally once daily for 4 consecutive days in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Placebo tablets, orally once daily for 4 consecutive days in the evening
Study: NCT03826862

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT three-dimensional reconstruction
Description: All patients will receive CT three dimensional reconstruction before surgery
Study: NCT03013439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: The trial is a dose escalating trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: The trial is a dose escalating trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: The trial is a dose escalating trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: The trial is a dose escalating trial.
Study: NCT00005831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00150839

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirtazapine
Description: Patients receive mirtazapine 45mg and placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Patients receive mirtazapine 45mg and venlafaxine 300mg.
Study: NCT01107587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' human rotavirus vaccine 444563
Description: Oral, two doses.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, two doses.
Study: NCT03331146

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A placebo (saline infusion) will be administered after induction of general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A placebo (saline infusion) will be administered after induction of general anesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Nitrite
Description: Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite
Description: Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
Study: NCT00805623

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sucrose
Description: 1 cc of sucrose 33.5% with or without pacifier

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: 1 cc of sucrose 33.5% with or without pacifier
Study: NCT03036787

Intervention type: BEHAVIORAL
Intervention: family based intervention
Description: behavioural advises to family for normal motor development

Intervention type: BEHAVIORAL
Intervention: family based intervention
Description: behavioural advises to family for normal motor development
Study: NCT02968563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Administered intravenously
Study: NCT02909452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A selective humanized monoclonal antibody (mAb)
Study: NCT02062333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esmolol
Description: 500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
Study: NCT03442621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant Fasted
Description: Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant with a high fat breakfast
Description: Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant with a moderate breakfast
Description: Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
Study: NCT03240679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acell MatriStem® Surgical Matrix
Description: Extracellular matrix (ECM) product that is composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling to facilitate constructive healing following endoscopic submucosal resection (EMR). Covers the defect site following mucosal resection using endoscopy clips or X-tac. The device will remain attached to the esophagus and integrate with native tissue over time.
Study: NCT02109120

Intervention type: PROCEDURE
Intervention: vein blood collection
Description: 5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
Study: NCT01996826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin® (bevacizumab)
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl & Refresh Liquigel
Description: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
Study: NCT01758185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant hepatitis b vaccine
Description: 0.5ml intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recombinant hepatitis b vaccine
Description: 0.5ml intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aleph influenza vaccine
Description: 0.5ml intramuscular

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aleph influenza vaccine
Description: 0.5ml intramuscular
Study: NCT04564456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent
Description: 2 inhalations of Test oproduct in one study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADVAIR DISKUS® 500/50
Description: 2 inhalations Reference product in one study period
Study: NCT01086540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: CMRI
Description: Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CMRI
Description: Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
Study: NCT00774592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bahamian Focus on Older Youth (BFOOY)
Description: 10 session HIV prevention program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bahamian Focus on Older Youth (BFOOY)
Description: 10 session HIV prevention program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Family Life Curriculum (HFLE)
Description: Standard Grade 10 curriculum

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health and Family Life Curriculum (HFLE)
Description: Standard Grade 10 curriculum
Study: NCT03006718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMIS for Pain Management App
Description: At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
Study: NCT01655082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0116 transdermal patch
Description: One patch per day (during 24 hours) for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine transdermal patch
Description: One patch per day (during 24 hours) for 21 days
Study: NCT00078832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: aromatase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Arimidex placebo
Study: NCT01030263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorescence-aided confocal endomicroscopy guided biopsy.
Description: Fluorescence-aided confocal endomicroscopy guided biopsy.

Intervention type: OTHER
Group type: OTHER
Intervention: Random four-quadrant biopsies.
Description: Random four-quadrant biopsies.
Study: NCT01455948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relieva Balloon Sinuplasty™ System
Description: Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Endoscopic Sinus Surgery
Description: Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
Study: NCT03191448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation
Description: Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDBA
Description: Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen wound dressing
Description: Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
Study: NCT03608111

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single task balance training
Description: single task balance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single task balance training
Description: single task balance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task balance training
Description: dual task balance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dual task balance training
Description: dual task balance training
Study: NCT02689011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.